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COST EFFECTIVENESS ANALYSIS OF RIFAXIMIN FOR THE TREATMENT 
OF ACUTE HEPATIC ENCEPHALOPATHY
Rivas R1, Cerezo O2, Zapata L1
1Guia Mark, Mexico, DF, Mexico, 2Instituto Nacional de Cancerología, Mexico, DF, Mexico
OBJECTIVES: Cirrhosis and its complications, such as hepatic encephalopathy (HE) 
are the sixth cause of general mortality in Mexico. The objective of this study is to 
evaluate a cost-effectiveness relationship of medications used to treat hepatic 
encephalopathy from the perspective of the Mexican Institute of Social Security 
(IMSS). METHODS: Cost-effectiveness analysis of treatments used for acute hepatic 
encephalopathy, based in a decision tree model, and considering a temporal horizon 
of 14 days, from the perspective of public health institutions. Existing relevant 
therapeutic alternatives available at the IMSS are: lactulose, L-ornithine L-aspartate 
(LOLA), neomycin and rifaximin (the new alternative). Proposed effectiveness measure 
based on available published studies and based on evidence: Percentage of patients 
with improvement in signs and symptoms of hepatic encephalopathy. Only direct 
medical costs are considered for the analysis, obtained from unitary medical attention 
costs reported by IMSS. A univariated sensitivity analysis, using relevant variables 
(price and effectiveness) and discount’s rates escenarios were performed. RESULTS: 
Treatment costs for each alternative (1 USD = 13.5 MXN $) totaled: lactulose 
US$3294, LOLA US$3297, neomycin US$3301 and rifaximin US $3312. In relation 
to effectiveness, the percentage of patients who presented improved signs and 
symptoms for each alternative is as follows: lactulose and LOLA 55%, neomycin 64% 
and riﬁxamin 90%. Cost effectiveness ratios are: lactulose US$5991, LOLA $5995, 
neomycin US$5157 and riﬁxamin US$3680. The incremental cost effectiveness 
analysis indicates that LOLA and neomycin are surpassed by lactulose and rifaximin, 
which are located on the efﬁciency line. Rifaximin can lessen hospital stays by at least 
one day and cut down at least one medical consultation. If these factors are taken into 
account for the sensitivity analysis, rifaximin takes the lead as dominating alternative. 
CONCLUSIONS: Rifaximin is a highly cost effective alternative for treating acute 
hepatic encephalopathy from an institutional perspective in Mexico.
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COST UTILITY ANALYSIS OF CERTOLIZUMAB PEGOL VERSUS 
NATALIZUMB MAINTENANCE THERAPY FOR CROHN’S DISEASE
Wu B
University of Florida, Gainesville, FL, USA
OBJECTIVES: To determine whether certolizumab pegol was a cost-effective strategy 
compared with natalizumab for patients with moderate to severe Crohn’s disease. 
METHODS: A Markov model was constructed to simulate the progression of adult 
Crohn’s patients. Transitions were estimated from published clinical trials of certoli-
zumab pegol and natalizumab. The costs were discounted at 3% over 5 years. The 
primary effectiveness measurement was quality-adjusted life years. One-way and 
probabilistic sensitivity analyses were performed by varying the transition probabili-
ties, costs and health state preferences. RESULTS: The treatment with natalizumab 
yielded 39.295 more quality-adjusted life years compared with the treatment with 
certolizumab pegol. The incremental cost-effectiveness ratio was $164,431/quality-
adjusted life year at 5 years. Sensitivity analysis demonstrated that the model ﬁndings 
were robust and remained in the 95% conﬁdence interval of $70,594 - $393,281. As 
one of the most inﬂuential variables, a reduction in the unit price of natalizumab by 
13.8% resulted in an incremental cost-effectiveness ratio below $80,000 per quality-
adjusted life year. CONCLUSIONS: The treatment with natalizumab yielded more 
quality-adjusted life years compared with the treatment with certolizumab pegol in 
moderate and severe Crohn’s patients. However, the cost was considerable.
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PHARMACOECONOMIC ANALYSIS OF THE EFFECTS OF SECONDARY 
BACTERIAL RESISTANCE IN THE MULTI-DEPARTMENTAL HOSPITAL 
ON TREATMENT EFFICACY IN COMPLICATED ABDOMINAL 
INFECTIONS
Kolbin AS1, Sidorenko S2, Zagorodnikova K1, Klimko N3, Koroleva O1
1Saint -Petersburg State University, Saint Petersburg, Russia, 2Ñhildren Infections Research 
Institute, Saint Petersburg, Russia, 3Saint - Petersburg Medical Academy of Postgraduate 
Education, Saint Petersburg, Russia
OBJECTIVES: To evaluate the clinical-economic value of ertapenem therapy in 
patients with complicated abdominal infections (CAI) vs. standard combination 
therapy considering the development of bacterial resistance in the Russian settings 
METHODS: The pharmacoeconomic analysis utilized the cost-effectiveness analysis 
(CER). If the efﬁcacy and the cost of any of the studied regimens exceeded those of 
the other regimen, an incremental analysis was carried out (ICERs). The decision 
analytic model was based on the clinical studies of CAI treatment. Efﬁcacy and safety 
data were based on additional analyses of a randomised, double blind, multinational 
trial of ceftriaxone plus metronidazole, ciproﬂoxacin plus metronidazole, ertapenem. 
For the assessment of the effects of secondary bacterial resistance on treatment efﬁcacy 
in CAI we utilized results obtained with a “susceptible – infected – susceptible” model 
(SIS-model) for development of antimicrobial resistance (i. e. reduction of the suscep-
tibility /effectiveness ratio observed with time), for ceftriaxone / metronidazole, cip-
roﬂoxacin / metronidazole, ertapenem. To evaluate the degree of inaccuracy of the 
results, sensitivity analyses were performed. RESULTS: It was established that the 
mode of starting treatment of CAP combination therapy ciproﬂoxacin / metronidazole 
was more expensive ($3153) in comparison with the use of ertapenem ($2860) and 
ceftriaxone/metronidazole ($2579). The CER established that the mode of starting 
treatment of CAP with ertapenem was both more effective and less expensive in 
comparison with the use of ciproﬂoxacin / metronidazole. The SIS-model showed that 
sensitivity to ertapenem bacterial agent is kept signiﬁcantly longer then to ceftriaxone 
/ metronidazole and ciproﬂoxacin / metronidazole (up to 60 month).The analysis of 
the alternative, whose cost of treatment of CAR was equal in all groups, has shown 
that the strategy using ertapenem was dominating. CONCLUSIONS: At CAI, such as 
a secondary peritonitis when the basic activators are Escherichia ñoli, Klebsiella 
pneumoniae and Bacteroides Fragillis it is more expedient to begin treatment with 
ertapenem.
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CANADIAN COST-UTILITY ANALYSIS OF INITIATION AND 
MAINTENANCE TREATMENT WITH ANTI-TNF DRUGS FOR 
REFRACTORY CROHN’S DISEASE
Blackhouse G1, Xie F1, Assasi N1, Gaebel K2, Marshall J3, Irvine EJ4, Robertson D1, 
Goeree R1
1PATH Research Institute, McMaster University, Hamilton, ON, Canada, 2St Joseph’s 
Healthcare, Hamilton, ON, Canada, 3Hamilton Health Sciences,McMaster University, 
Hamilton, ON, Canada, 4St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada
OBJECTIVES: Crohn’s disease (CD) is a chronic inﬂammatory disease of the gastroin-
testinal tract which can cause abdominal pain, diarrhea and weight loss. Anti-TNFα 
drugs are being used more often and earlier in the disease course of patients with CD 
who have aggressive disease. However, these medications are quite expensive. The 
objective of this study is to evaluate the cost-utility of two anti-TNF drugs (inﬂiximab, 
adalimumab) for refractory CD. METHODS: A Markov model was used to estimate 
the costs and utilities (QALYs) of three treatments (usual care, inﬂiximab, adalimu-
mab) over a 5 year time horizon. After initial treatment, patients can achieve complete 
remission, treatment response or remain in a drug refractory health state. Patients 
achieving remission or response remain at risk of relapse during each 3 month model 
cycle. Patients in the drug refractory health state can either stay in that health state 
or have surgery during each cycle. Estimated costs and utility values were then assigned 
to the various model health states. Model input parameters, including initial response 
rates, relapse rates and utility values were derived from the published literature. 
RESULTS: Usual care had both the lowest expected costs ($17,017) and QALYs 
(2.555), while inﬂiximab had both the highest expected costs ($54,084) and QALYs 
(2.721). The incremental cost per QALY moving from usual care to adalimumab and 
from adalimumab to inﬂiximab was estimated to be to be $193,305 and $451,165, 
respectively. CONCLUSIONS: Based on common willingness to pay thresholds, 
ant-TNF drugs would not be perceived as a cost effective treatment for refractory CD.
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OPEN VERSUS LAPAROSCOPIC PROCEDURES FOR 
CHOLECYSTECTOMY SURGERY: A COST-UTILITY ANALYSIS, UNDER 
THE BRAZILIAN PUBLIC PAYER PERSPECTIVE
Nasciben V1, Saggia MG1, Sanchez JF2
1Johnson & Johnson, Sao Paulo-SP, Brazil, 2Johnson & Johnson, Bogota, Colombia
OBJECTIVES: To assess the economic impact of the incorporation of the laparoscopic 
procedure in terms of costs, QALYs, reduction of the convalescence period and com-
plication rates under the Brazilian public payer perspective. METHODS: An analytic 
decision-tree model was built to estimate costs and outcomes of the cholecystectomy 
surgery comparing the main differences between open and laparoscopic techniques 
(minimally invasive procedures), based on Brazilian guidelines for HTA (Vianna, 
2007). LAP reduces the probability of nosocomial infection (NI) from 8.93% to 2.6% 
(Brill 2008), the length-of-stay (LOS) from 3 days to 1 day and return to work in 
22.51 days (Keus 2006) when compared to OP. Only direct medical costs (physician 
fees, hospital length-of-stay (LOS) and materials were based on public lists (SUS/
SIGTAP and SIMPRO, 2009). A panel of specialists was conducted to validate the 
model. One-month timeframe was considered, based on intra and post-operative 
periods; consequently a discount rate was not necessary. One-way sensitivity analyses 
were performed to assess the robustness of the results. RESULTS: In terms of out-
comes, for each 1000 surgeries the LAP procedure can reduce the number of NI cases 
in 53, sepsis in 4 and deaths in 2. Total costs (including complications and devices) 
were higher R$ 2,271 for LAP than OP (R$3135 versus R$864), mainly because of 
laparoscopic devices’ costs (R$2385). However, LAP technique allowed the reduction 
on complication costs in 34% (from R$231 for OP to R$151 for LAP). Due to lower 
complication rates, LAP showed a 0.1085 higher QALY than OP (0.8357 for OP vs. 
0.9443 for LAP). In the end, the incremental cost-utility ratio for the incorporation 
of the LAP procedure was R$20,920 per QALY. CONCLUSIONS: Findings suggest 
LAP approach to cholecystectomy as a safer and cost-effective choice for cholecystec-
tomy surgery, under the Brazilian public system.
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UTILIZATION AND COST OF PEGINTERFERON PLUS RIBAVIRIN 
COMBINATION THERAPY IN THE MANAGEMENT OF CHRONIC 
HEPATITIS C VIRUS IN EUROPE
Davis KL1, Mitra D1, Leteneux C2, Bapat B1, Naujoks C2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, 
Switzerland
OBJECTIVES: To document real-world utilization patterns and costs of peginterferon 
plus ribavirin combination therapy in the management of chronic hepatitis C virus 
(C-HCV) in Europe. METHODS: Patient charts from clinics in the UK, France, 
Germany, Spain, and Italy were retrospectively reviewed by 240 physicians (∼48 per 
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country). Patient inclusion criteria were: C-HCV diagnosis within past 5 years; treated 
with peginterferon alfa-2a or alfa-2b plus ribavirin combination therapy (PEG2A+R 
or PEG2B+R, respectively); age ≥18 years; no diagnoses of hepatitis B or HIV/AIDS; 
≥1 year follow-up post-treatment initiation; no clinical trial participation. Treatment 
dosing, duration, compliance, and costs (in 2009 3) were descriptively analyzed at the 
patient level. Published drug prices were used in all cost calculations. RESULTS: 
Hepatology, gastroenterology, and internal medicine were the predominant physician 
specialties observed, representing 22%, 30%, and 25%, respectively, of all physicians 
recruited. A total of 804 patients (∼160 per country) were identiﬁed, of whom 65% 
were male with mean age of 46 years. More patients initiated PEG2A+R (69%) than 
PEG2B+R (31%). For both regimens, all major ribavirin doses (800, 1000, and 
1200 mg) were seen, representing 36%, 35%, and 22%, respectively, of PEG2A+R 
patients and 39%, 47%, and 14%, respectively, of PEG2B+R patients. Mean treat-
ment duration was ∼35 weeks for both PEG2A+R and PEG2B+R, with distribution 
spikes at 24 and 48 weeks. Treatment compliance was relatively high, with ∼75% of 
patients completing therapy as planned regardless of regimen. Mean weekly treatment 
costs ranged from 3280 to 3350 depending on the ribavirin dose. Mean total regimen 
costs were estimated at 311,827 and 311,109 per patient for PEG2A+R and PEG2B+R, 
respectively. CONCLUSIONS: Peginterferon-based regimens, although a mainstay of 
C-HCV management, are costly. Public health systems bearing the high economic 
burden of C-HCV treatment should be mindful of these costs when considering for-
mulary access for alternative treatments.
GASTROINTESTINAL DISORDERS – Patient-Reported Outcomes Studies
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SELECTING CHRONIC CONSTIPATION (CC) CLINICAL TRIAL 
ENDPOINTS: INCORPORATING THE PATIENT’S VOICE
Ervin CM1, Fehnel SE1, Carson RT2, Kurtz CB3, Shiff SJ2, Johnston JM3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Forest Research Institute, Jersey 
City, NJ, USA, 3Ironwood Pharmaceuticals, Cambridge, MA, USA
OBJECTIVES: 1. Identify a comprehensive set of symptoms for measurement in CC 
clinical trials. 2. Achieve saturation and provide support for the content validity of 
the corresponding set of endpoints in accordance with FDA’s PRO guidance. 
METHODS: Twenty-eight in-depth interviews were conducted in two phases, in dif-
ferent geographic locations, with participants meeting modiﬁed Rome II criteria for 
CC. A semi-structured interview guide was used, beginning with a series of open-ended 
questions to elicit all relevant symptoms, followed by interviewer probes to fully 
understand the relationships among the concepts. Multiple rating and ranking 
methods were used to develop a subset of CC symptoms of greatest importance to 
patients. For example, participants were asked to identify their most bothersome CC 
symptoms, as well as those in which they would most like to see an improvement with 
treatment. RESULTS: When asked to describe their CC symptoms, the patients 
reported 62 potentially distinct concepts: 12 bowel symptoms, 21 abdominal symp-
toms, 25 additional physical symptoms, and 4 mental or emotional issues. Patient 
descriptions of symptoms revealed that symptom terms were highly related and/or 
could be considered secondary to CC. Results of the subsequent rating and ranking 
tasks suggest that the concepts of stool frequency, stool consistency, straining, incom-
plete evacuation, abdominal pain, abdominal discomfort, and bloating were distinct 
and comprise patients’ most bothersome symptoms. Further, improvements in these 
symptoms would constitute an improvement in patients’ CC overall, and PRO items 
addressing these symptoms were found to be clear and comprehensive. CONCLU-
SIONS: Patient input is vital to identify the full spectrum of symptoms, and to 
determine an optimal set of clinical trial endpoints. Interview results suggest that a 
variety of techniques may be necessary to demonstrate concept saturation and identify 
those symptoms which accurately represent a functional disorder such as CC.
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PSYCHOMETRIC PROPERTIES OF THE TREATMENT SATISFACTION 
QUESTIONNAIRE FOR MEDICATION IN PATIENTS WITH 
GASTROESOPHAGEAL REFLUX DISEASE
Bharmal M1, Cascade E2, Gemmen E1
1Quintiles, Falls Church, VA, USA, 2iGuard, Falls Church, VA, USA
OBJECTIVES: The Treatment Satisfaction Questionnaire for Medication Version 1.4 
(TSQM) is a widely used 14-item generic instrument to assess patients’ satisfaction with 
medication, providing scores on four scales—Effectiveness, Side Effects, Convenience 
and Global Satisfaction. The objectives of this study were to assess the psychometric 
properties of the TSQM in a community-based population in the US receiving treat-
ments for gastroesophageal reﬂux disease (GERD). METHODS: Patients were 
recruited for this study from multiple sources including physician, pharmacy and online 
referrals to a medication monitoring service (www.iGuard.org). A random sample of 
patients using GERD treatments were invited to complete the TSQM online. Internal 
consistency of the TSQM scales was evaluated using item-total correlations and Cron-
bach’s alpha. Known-group validity was evaluated using analysis of covariance models 
based on the association of TSQM scale scores with a global item of patient rating the 
effectiveness of their medication. RESULTS: Data from a total of 1872 patients with 
at least one non-missing TSQM scale score were analyzed for this study. The mean (SD) 
age was 54.3 (12.4) years, 71.6% were females, 15.1% reported mild, 53.2% reported 
moderate and 31.7% reported severe disease severity. The TSQM scales had very good 
internal consistency, all item-total correlations were greater than 0.60. Cronbach’s 
alpha for Effectiveness scale was 0.92, Side Effects scale was 0.89, Convenience scale 
was 0.83 and Global Satisfaction scale was 0.89. After adjusting for patient age, gender, 
self-reported severity, GERD therapeutic class and number of concomitant medica-
tions, as expected, all the TSQM scales scores were signiﬁcantly associated with the 
global rating for medication effectiveness (all p < 0.0001), with higher TSQM scores 
among patients who believed that their medication completely cured their condition 
compared to those who rated medication effectiveness lower. CONCLUSIONS: The 
study provides evidence that the TSQM is a psychometrically sound and valid measure 
to assess patient satisfaction with GERD medication.
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PAIN AFTER LIVER TRANSPLANT: A CROSS SECTIONAL STUDY
Cavanaugh TM1, Waddell D1, Gorevski E1, Gutman K1, Neff GW2, Rudich SM2, 
Martin-Boone J1
1James L Winkle College of Pharmacy, Cincinnati, OH, USA, 2The University Hospital, 
Cincinnati, OH, USA
OBJECTIVES: There are multiple potential sources of pain in liver transplant (txp) 
pts with consequences of delayed healing, higher health care costs and decreased 
quality of life. The objective of this study was to assess the incidence, quality, manage-
ment and treatment satisfaction of pain after liver txp. METHODS: This was a 
cross-sectional analysis of ambulatory liver txp pts. A questionnaire was developed 
using a modiﬁed Brief Pain Inventory. Pts described location, intensity, and pain 
quality. Pain symptoms were categorized as neuropathic, nociceptive and mixed pain. 
RESULTS: Sixty-eight pts were surveyed. Eleven pts were within 3 months of txp 
(Group 1) and 57 pts were > 3 mos post txp, mean of 60 ± 59 mos (Group 2). There 
were 38 males, 30 females; 10 AA, 58 Cauc; mean age 56 ± 9 yr. Forty-three pts 
(63%) reported having pain today: 90% of Group 1 and 58% of Group 2. Sixty-two 
percent of their pain was reported as new since txp. Forty-six percent of pain was 
nociceptive, 12% neuropathic and 42% mixed. Pain was most often in the lower 
extremities and lower back. Current pain was reported as being 4.5 (median) on a 
scale of 1–10. Pain interfered with sleep and normal work. Thirty-four pts were taking 
pain medications. Of these, more than 50% were taking 2 or more medication classes. 
Only 5 pts were being followed by a pain specialist, but 80% of these were completely 
satisﬁed with their pain management compared to 55% when followed by primary 
care and 40% when followed by the transplant team. CONCLUSIONS: Half of pts 
post liver txp have pain that impacts their lives and most often requires long term 
medication use for pain relief. Pts followed by pain specialists are more satisﬁed with 
their management than those followed by other health care providers.
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CORRESPONDENCE OF MULTIPLE HEALTH OUTCOMES MEASURES IN 
RESPONSIVENESS TO MMXTM MESALAMINE TREATMENT FOR 
PATIENTS WITH ULCERATIVE COLITIS
Yen L1, Yarlas A2, Hodgkins P1
1Shire Pharmaceuticals, Wayne, PA, USA, 2QualityMetric Inc., Lincoln, RI, USA
OBJECTIVES: To understand how multiple health outcomes (HO) instruments could 
better measure health-related quality of life (HRQoL) and work productivity in ulcera-
tive colitis (UC) patients, we examined interrelations among three HO instruments 
used in a clinical trial: a generic measure (SF-12v2), a disease speciﬁc measure (Short-
ened Inﬂammatory Bowel Disease [IBD] Questionnaire [SIBDQ]), and a work produc-
tivity measure (Work Productivity and Activity Impairment Questionnaire for UC 
[WPAI : UC]). METHODS: Mild-to-moderate UC patients received MMX mesalamine 
daily for 8 weeks in an open-label study. HO was measured at baseline and eight-
weeks. SF-12v2 measures 8 domains of generic HRQoL. SIBDQ measures 4 domains 
of IBD-related QoL: bowel symptoms, systemic symptoms, emotional function, and 
social function. The WPAI : UC measures 4 dimensions of work-related productivity 
impacted by UC: absenteeism, presenteeism, work impairment, and activity impair-
ment. Repeated-measures ANOVAs examined changes in HO scores. Associations 
among instruments in detecting HO change were assessed by intercorrelations among 
change scores, and correlations with patient-reported symptoms: bowel movement 
frequency (BMF) and rectal bleeding severity (RBS). RESULTS: 107 patients com-
pleted both assessments. Improvement occurred in 18 of 19 HO scale and summary 
scores (p < 0.05 for differences), indicating each instrument was responsive to treat-
ment. Correlations indicated moderate associations in the predicted directions for 
change scores among all three instruments: the average correlation was 0.47 between 
SF-12v2 and SIBDQ scales, −0.39 between SF-12v2 and WPAI : UC scales, and −0.48 
between SIBDQ and WPAI : UC scales. Improvement in scale scores for all measures 
was moderately correlated with improvement in both BMF and RBS (magnitude of 
average correlations ranged from 0.29 to 0.47). CONCLUSIONS: Instruments meas-
uring different aspects of HO showed consistent responsiveness to eight weeks’ treat-
ment with MMX mesalamine in mild-to-moderate UC patients. Similar results 
obtained using different HO instruments conﬁrm the treatment effect, and also indi-
cate convergent validity among these instruments within this patient population.
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CURRENT EVIDENCE REGARDING THE HEPATITIS C PATIENT 
EXPERIENCE
Bauch PM1, Sterling RK2, Clement LM1, Velez FF3
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OBJECTIVES: To conduct a systematic review of studies reporting primary hrQoL 
data among patients with Hepatitis C and assess implications for adherence, work 
